Literature DB >> 18614532

Multiple cyclin kinase inhibitors promote bile acid-induced apoptosis and autophagy in primary hepatocytes via p53-CD95-dependent signaling.

Guo Zhang1, Margaret A Park, Clint Mitchell, Teneille Walker, Hossein Hamed, Elaine Studer, Martin Graf, Mohamed Rahmani, Seema Gupta, Philip B Hylemon, Paul B Fisher, Steven Grant, Paul Dent.   

Abstract

Previously, using primary hepatocytes residing in early G1 phase, we demonstrated that expression of the cyclin-dependent kinase (CDK) inhibitor protein p21Cip-1/WAF1/mda6 (p21) enhanced the toxicity of deoxycholic acid (DCA) + MEK1/2 inhibitor. This study examined the mechanisms regulating this apoptotic process. Overexpression of p21 or p27(Kip-1) (p27) enhanced DCA + MEK1/2 inhibitor toxicity in primary hepatocytes that was dependent on expression of acidic sphingomyelinase and CD95. Overexpression of p21 suppressed MDM2, elevated p53 levels, and enhanced CD95, BAX, NOXA, and PUMA expression; knockdown of BAX/NOXA/PUMA reduced CDK inhibitor-stimulated cell killing. Parallel to cell death processes, overexpression of p21 or p27 profoundly enhanced DCA + MEK1/2 inhibitor-induced expression of ATG5 and GRP78/BiP and phosphorylation of PKR-like endoplasmic reticulum kinase (PERK) and eIF2alpha, and it increased the numbers of vesicles containing a transfected LC3-GFP construct. Incubation of cells with 3-methyladenine or knockdown of ATG5 suppressed DCA + MEK1/2 inhibitor-induced LC3-GFP vesicularization and enhanced DCA + MEK1/2 inhibitor-induced toxicity. Expression of dominant negative PERK blocked DCA + MEK1/2 inhibitor-induced expression of ATG5, GRP78/BiP, and eIF2alpha phosphorylation and prevented LC3-GFP vesicularization. Knock-out or knockdown of p53 or CD95 abolished DCA + MEK1/2 inhibitor-induced PERK phosphorylation and prevented LC3-GFP vesicularization. Thus, CDK inhibitors suppress MDM2 levels and enhance p53 expression that facilitates bile acid-induced, ceramide-dependent CD95 activation to induce both apoptosis and autophagy in primary hepatocytes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18614532      PMCID: PMC2528985          DOI: 10.1074/jbc.M803444200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  38 in total

1.  Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage.

Authors:  N H Chehab; A Malikzay; E S Stavridi; T D Halazonetis
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-23       Impact factor: 11.205

2.  Down-regulation of cholesterol 7alpha-hydroxylase (CYP7A1) gene expression by bile acids in primary rat hepatocytes is mediated by the c-Jun N-terminal kinase pathway.

Authors:  S Gupta; R T Stravitz; P Dent; P B Hylemon
Journal:  J Biol Chem       Date:  2001-02-13       Impact factor: 5.157

Review 3.  Enterohepatic circulation: physiological, pharmacokinetic and clinical implications.

Authors:  Michael S Roberts; Beatrice M Magnusson; Frank J Burczynski; Michael Weiss
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 4.  New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment?

Authors:  Olivier Coqueret
Journal:  Trends Cell Biol       Date:  2003-02       Impact factor: 20.808

5.  Activation and role of mitogen-activated protein kinases in deoxycholic acid-induced apoptosis.

Authors:  D Qiao; E D Stratagouleas; J D Martinez
Journal:  Carcinogenesis       Date:  2001-01       Impact factor: 4.944

6.  Inhibition of the MAPK and PI3K pathways enhances UDCA-induced apoptosis in primary rodent hepatocytes.

Authors:  Liang Qiao; Adly Yacoub; Elaine Studer; Seema Gupta; Xin Yan Pei; Steven Grant; Philip B Hylemon; Paul Dent
Journal:  Hepatology       Date:  2002-04       Impact factor: 17.425

7.  Deoxycholic acid (DCA) causes ligand-independent activation of epidermal growth factor receptor (EGFR) and FAS receptor in primary hepatocytes: inhibition of EGFR/mitogen-activated protein kinase-signaling module enhances DCA-induced apoptosis.

Authors:  L Qiao; E Studer; K Leach; R McKinstry; S Gupta; R Decker; R Kukreja; K Valerie; P Nagarkatti; W El Deiry; J Molkentin; R Schmidt-Ullrich; P B Fisher; S Grant; P B Hylemon; P Dent
Journal:  Mol Biol Cell       Date:  2001-09       Impact factor: 4.138

8.  Regulation of p53 stability by Mdm2.

Authors:  M H Kubbutat; S N Jones; K H Vousden
Journal:  Nature       Date:  1997-05-15       Impact factor: 49.962

9.  ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage.

Authors:  R Maya; M Balass; S T Kim; D Shkedy; J F Leal; O Shifman; M Moas; T Buschmann; Z Ronai; Y Shiloh; M B Kastan; E Katzir; M Oren
Journal:  Genes Dev       Date:  2001-05-01       Impact factor: 11.361

10.  Cyclin kinase inhibitor p21 potentiates bile acid-induced apoptosis in hepatocytes that is dependent on p53.

Authors:  Liang Qiao; Robert McKinstry; Seema Gupta; Donna Gilfor; Jolene J Windle; Philip B Hylemon; Steven Grant; Paul B Fisher; Paul Dent
Journal:  Hepatology       Date:  2002-07       Impact factor: 17.425

View more
  32 in total

1.  The decreased expression of Beclin-1 correlates with progression to esophageal adenocarcinoma: the role of deoxycholic acid.

Authors:  Heather B Roesly; Mohammad R Khan; Hwu Dau Rw Chen; Kimberly A Hill; Nirushan Narendran; George S Watts; Xiaoxin Chen; Katerina Dvorak
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-02-02       Impact factor: 4.052

2.  Inhibition of multiple protective signaling pathways and Ad.5/3 delivery enhances mda-7/IL-24 therapy of malignant glioma.

Authors:  Hossein A Hamed; Adly Yacoub; Margaret A Park; Patrick J Eulitt; Rupesh Dash; Devanand Sarkar; Igor P Dmitriev; Maciej S Lesniak; Khalid Shah; Steven Grant; David T Curiel; Paul B Fisher; Paul Dent
Journal:  Mol Ther       Date:  2010-02-23       Impact factor: 11.454

3.  The viral restriction factor tetherin prevents leucine-rich pentatricopeptide repeat-containing protein (LRPPRC) from association with beclin 1 and B-cell CLL/lymphoma 2 (Bcl-2) and enhances autophagy and mitophagy.

Authors:  Jing Zou; Wenjiao Li; Anisha Misra; Fei Yue; Kun Song; Qi Chen; Guanghua Guo; Jinglin Yi; Jason T Kimata; Leyuan Liu
Journal:  J Biol Chem       Date:  2015-01-28       Impact factor: 5.157

4.  Obatoclax and lapatinib interact to induce toxic autophagy through NOXA.

Authors:  Yong Tang; Hossein A Hamed; Nichola Cruickshanks; Paul B Fisher; Steven Grant; Paul Dent
Journal:  Mol Pharmacol       Date:  2012-01-04       Impact factor: 4.436

5.  Sorafenib activates CD95 and promotes autophagy and cell death via Src family kinases in gastrointestinal tumor cells.

Authors:  Margaret A Park; Roland Reinehr; Dieter Häussinger; Christina Voelkel-Johnson; Besim Ogretmen; Adly Yacoub; Steven Grant; Paul Dent
Journal:  Mol Cancer Ther       Date:  2010-08-03       Impact factor: 6.261

Review 6.  Autophagy paradox and ceramide.

Authors:  Wenhui Jiang; Besim Ogretmen
Journal:  Biochim Biophys Acta       Date:  2013-09-19

7.  Microtubule-associated protein 1S (MAP1S) bridges autophagic components with microtubules and mitochondria to affect autophagosomal biogenesis and degradation.

Authors:  Rui Xie; Susan Nguyen; Kerstin McKeehan; Fen Wang; Wallace L McKeehan; Leyuan Liu
Journal:  J Biol Chem       Date:  2011-01-24       Impact factor: 5.157

8.  OSU-03012 interacts with lapatinib to kill brain cancer cells.

Authors:  Laurence Booth; Nichola Cruickshanks; Thomas Ridder; Ching-Shih Chen; Steven Grant; Paul Dent
Journal:  Cancer Biol Ther       Date:  2012-09-18       Impact factor: 4.742

9.  A genetic screen in Drosophila reveals novel cytoprotective functions of the autophagy-lysosome pathway.

Authors:  Andrew M Arsham; Thomas P Neufeld
Journal:  PLoS One       Date:  2009-06-29       Impact factor: 3.240

10.  Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation.

Authors:  Margaret A Park; Guo Zhang; Aditi Pandya Martin; Hossein Hamed; Clint Mitchell; Philip B Hylemon; Martin Graf; Mohamed Rahmani; Kevin Ryan; Xiang Liu; Sarah Spiegel; James Norris; Paul B Fisher; Steven Grant; Paul Dent
Journal:  Cancer Biol Ther       Date:  2008-10-12       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.